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Objective: The aim of this study was to compare the efficacy of augmenting trabeculectomy with 
subconjunctival mitomycin C (TMMC) versus 5-fluorouracil (T5-FU) in lowering intraocular 
pressure (IOP).
Methods: Forty eyes from 40 patients referred to the Nikoukari Ophthalmology University 
Hospital, Tabriz University of Medical Sciences, Tabriz, Iran, were enrolled in a randomized 
clinical trial. Patients with high-risk open angle glaucoma were allocated to receive either 
subconjunctival TMMC or T5-FU.
Results: Mean overall preoperative IOP was 30.8 mmHg. Mean preoperative IOPs in the TMMC 
and T5-FU groups were 31.2 ± 9.8 and 30.6 ± 9.9 mmHg, respectively. Postoperatively, mean 
IOPs were 11.4.3 ± 4.9 and 13.6 ± 3.9 mmHg, respectively for TMMC and T5-FU groups after 
6 months. In spite of some existing descriptive differences in IOP between the groups, statistical 
tests showed no difference in mean and median IOP. Three cases of hypotonia (IOP , 6 mmHg) 
and 1 case of epithelial keratitis were detected.
Conclusion: TMMC and T5-FU appeared to have similar efficacy in lowering IOP.
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Introduction
Trabeculectomy aims to decrease intraocular pressure (IOP) by allowing the passage of 
aqueous humor from the anterior chamber to the subconjunctival space. The main reason 
for failure of filtering surgery is fibroblast proliferation and subsequent scar formation 
at the surgical site. Recent ongoing research has found some remedies to prevent this, 
and improve surgical success by inhibiting scar formation. Antimetabolites, including 
mitomycin C (MMC) and 5-fluorouracil (5-FU), were first used to modify the wound-
healing response in the early 1980s. Although an optimum therapy with good efficacy 
and low complication rate is not yet available, MMC and 5-FU are currently used for this 
purpose. MMC is an antimetabolite used during the initial stages of a trabeculectomy to 
prevent excessive postoperative scarring and thus reduce the risk of failure.1 Similarly 
5-FU can be used for the same purpose.2 MMC and 5-FU are typically used in eyes 
at high risk for bleb failure, and are used by researchers and clinicians as adjuncts to 
trabeculcetomy surgery (herein, TMMC and T5-FU), but using different protocols and 
dosages. Most of the evidence on efficacy of TMMC and T5-FU is based on studies 
conducted separately for these two protocols rather than comparative randomized trials 
of TMMC and T5-FU. In spite of large numbers of studies conducted in this area, very Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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few randomized clinical trials have compared MMC and 
5-FU in a parallel design, and those available did not compare 
subconjunctival forms of both drugs. The aim of this study was 
to compare the efficacy of TMMC with T5-FU in lowering 
IOP in high-risk glaucoma patients.
Methods
A randomized clinical trial study was conducted in the 
Nikoukari Ophthalmology University Hospital, Tabriz, Iran. 
Forty eyes from 40 patients were enrolled. Using simple 
randomization in a parallel trial design, 18 patients were ran-
domly assigned to receive TMMC and 22 to receive T5-FU. 
In the TMMC group, MMC was injected subconjunctively at 
a dose of 0.02 mg via an 0.4 mm*20 mm needle 180 degrees 
from the operating site. Likewise, 5-FU was injected into 
subconjunctively at a dose of 5 mg. The inclusion criteria for 
this study were: 1) open angle glaucoma; 2) uncontrolled IOP; 
3) optic nerve damage and visual field restriction. Patients 
were then followed up for measurement of IOP and devel-
opment of possible complications. IOP was measured using 
the Goldmann applanation tonometer (Haag-Streit, Bern, 
Switzerland) on 5 occasions: at baseline, 2 weeks, 1 month, 
3 months, and 6 months afterwards.
The primary endpoint of the study was successful aug-
mented surgery, defined as a consistent IOP between 6 mmHg 
and 22 mmHg towards the end of the evaluation period.
Data were analyzed using STATA version 11 statistical 
software package. Trends in IOP and IOP distributions were 
compared descriptively over the 6-month study. The primary 
endpoint was compared between the trial groups. Relative risk 
of treatment success for TMMC compared with T5-FU was 
calculated along with 95% confidence intervals (CI). Mean 
and median tests were also used to compare IOP between 
groups. Kaplan–Meier curves and survival function tests 
were used to assess the effect of treatment on time to success. 
To control possible random disproportions in some background 
confounders, a Cox regression model was used. All the 
statistical tests were interpreted on a 2-tailed basis. The test 
results with a P-value , 0.05 were considered as statistically 
significant. The study protocol was approved by the ethics 
committee of Tabriz University of Medical Sciences.
Results
Men comprise 81% of the participants. Mean age was 
67.5 years (standard deviation 10 years). The youngest 
subject was 48 years old and the oldest was 83 years old. 
Mean preoperative IOP was 30.85 mmHg. Mean preoperative 
IOPs in the TMMC and T5-FU groups were 31.2 ± 9.8 and 
30.6 ± 9.9 mmHg, respectively. Postoperatively, mean IOPs 
were 11.4.3 ± 4.9 and 13.6 ± 3.9 mmHg, respectively, for 
TMMC and T5-FU after 6 months. Figure 1 shows that 
average IOP in both groups began to decrease sharply dur-
ing the first 2 weeks, then leveled off in the T5-FU group but 
continued to decrease slowly in the TMMC group.
A similar pattern of steeper IOP improvement trend was 
also found for the TMMC group when quartiles instead 
of means were compared. The distribution of IOP in the 
TMMC group changed from left-skewed to nearly-normal 
after 6 months (Figure 2).
In spite of some existing descriptive differences in IOP 
between the groups, statistical tests showed no difference in 
mean and median IOP. For the primary endpoint (consistent 
IOP between 6 mmHg and 22 mmHg towards the end of the 
evaluation period), treatment was successful in 88.9% and 
92.5% of subjects in TMMC and T5-FU groups, respectively. 
Two patients in the TMMC group and 1 patient in the T5-FU 
group did not have a successful outcome during the 6 months 
of follow-up: IOP in these 3 patients dropped to ,6 mmHg, 
which was regarded unsuccessful. The relative risk of 
success for TMMC compared with T5-FU was 0.93 (95% 
CI: 0.8–1.1).
Testing the survival functions of successful treatment did 
not show any statistically significant differences between the 
groups (Figure 3).
The Cox regression model did not help to detect possible 
differences in efficacy between groups. Three cases of 
hypotonia (IOP , 6 mmHg) and 1 case of epithelial keratitis 
were observed. No differences were detected between 
the groups.
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Figure 1 Error bar graph (95% confidence intervals of standard errors) comparing 
intraocular pressure (iOP) after trabeculectomy augmented with subconjunctival 
mitomycin C (TMMC) versus 5-fluorouracil (T5-FU).Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Discussion
Most of the evidence on efficacy of TMMC and T5-FU is 
based on studies conducted separately for these two protocols 
rather than comparative randomized trials. A recent review 
enrolled 11 placebo-controlled studies for MMC and 
concluded that MMC appears to reduce the relative risk 
of failure of trabeculectomy both in eyes at high risk of 
failure (relative risk 0.32, 95% CI: 0.20–0.53) and those 
undergoing surgery for the first time (relative risk 0.29, 95% 
CI: 0.16–0.53).1 Another systematic review partly by the same 
authors conducted earlier suggested that injection of low doses 
of 5-FU may not be effective.2 The before–after assessment 
of the effect of TMMC or T5-FU was quite obvious in our 
study although was not an objective of the study.
It is clear from published results that treatment protocols 
for augmented trabeculectomy vary widely, for example, 
in form of drug application (ie, injection vs sponge), 
application-injection site, timing, frequency, and dosage. 
This variation is doubled when two drugs are compared in a 
clinical trial. Our study was a randomized clinical trial study 
comparing TMMC and T5-FU. We retrieved 10 articles that 
compared the two methods either in an observational study 
or in a parallel clinical trial design.3–12 Table 1 compares the 
methodology of these studies.
The drugs were administered intraoperatively in most of 
these studies using soaked sponges. A few also used subcon-
junctival injection of 5-FU. Dosage and timing also differed 
among these studies. Nevertheless, as in our study, nearly 
all of these studies failed to detect statistically significant 
differences in success or development of complications 
between TMMC and T5-FU. One study found borderline 
statistical significance for lower mean IOP in TMMC than 
T5-FU.9 As in our study, some of these studies stated a 
descriptively higher success rate for TMMC. Our study results 
were consistent throughout different assessment methods 
such as comparing means, medians, quartiles, distribution 
patterns, and survival methods. Most of these studies tried 
to test the differences between groups in complications but 
found no difference. However, these studies’ power limits 
seem to be too low to enable differences in complication 
rates to be detected between groups. Register-based cohorts 
in high-income countries that have reliable patient registry 
databases could be a better way of answering this   question. 
In addition case-control studies can also be a valuable way 
of investigating this issue in countries lacking reliable 
databases.
The IOP decrement pattern in our study seemed to be 
more transient for T5-FU than for TMMC. Khaw et al found 
similar results in an animal study.13
Our survival analysis using Kaplan–Meier survival com-
parison and survival function tests did not show a significantly 
longer time for TMMC to achieve success. Among the studies 
discussed above, Palanca-Capistrano et al found similar 
results as ours when using the Kaplan–Meier and survival 
function tests to compare TMMC and T5-FU.6 Several factors 
are known to affect IOP, among which are corneal parameters 
such as corneal curvature. It is obligatory in observational 
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Figure 2 intraocular pressure (iOP) measured at baseline (1), 1 month (2), and 6 months (3) after surgery.
Note: in each histogram the left side shows the results for TMMC and the right side shows results for T5-FU.
Abbreviations: TMMC, trabeculectomy augmented with subconjunctival mitomycin C; T5-FU, trabeculectomy augmented with 5-fluorouracil.
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Figure 3 Kaplan–Meier curves comparing success rate of TMMC and T5-FU.
Abbreviations: TMMC, trabeculectomy augmented with subconjunctival mitomycin C; 
T5-FU, trabeculectomy augmented with 5-fluorouracil.Clinical Ophthalmology
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studies to measure and control these parameters. Considering 
the effect of randomization in clinical trials, the distribu-
tion of known and unknown confounders will be random; 
however, it is preferable to measure these parameters, even 
in randomized trials.
Based on our findings and available knowledge, it appears 
that TMMC and T5-FU have similar efficacy in augmenting 
trabeculectomy. However, considering the greater, but 
nonsignificant, efficacy of TMMC in some studies, including 
ours, future larger-scale clinical trials comparing the 
two methods may be able to detect a significant difference. 
Use of subconjunctival injections of MMC and 5-FU may 
be recommended also because of easier methodology and 
possibly less procedural variation.
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Table 1 Comparison of methods in observational and clinical trial studies comparing TMMC with T5-FU
Ref. Design Primary endpoint TMMC protocol T5-FU protocol
(12) rCT Achieving target iOP of  
21, 18, 15, 12 mmhg 
Topical MMC 0.2 mg/mL for 2 min Topical 5-FU 50 mg/mL for 5 min
(11) retrospective cohort Possible iOP mmhg MMC 200 µg/mL for 3–5 min 5-FU 50 mg/mL for 5 min (n = 37)
(9) rCT Possible iOP , 15 mmhg MMC 0.5 mg/mL for 3 1/2 min 5-FU 50 mg/mL for 5 min
(10) Multi-center rCT iOP MMC 0.4 mg/mL for 2 min 5-FU 50 mg/mL for 5 min
(8) retrospective cohort iOP , 21 mmhg 3–5 min exposure to 
0.5 mg/mL MMC
5-FU subconjunctival injections 
5 mg/0.1 mL
(3) retrospective cohort iOP # 21 mmhg MMC 0.2–0.5 mg/mL for 3–5 min 5-FU 50 mg/mL for 5 min
(4) retrospective cohort iOP , 21 mmhg MMC 0.5 mg/mL for 3 min 5-FU 50 mg/mL for 5 min
(5) rCT iOP , 20 mmhg MMC 0.2 mg 5-FU 5 mg subconjunctival injection
(6) rCT Time to iOP # 21 mmhg MMC 0.2 mg/mL for 2 min 5-FU 50 mg/mL 5 min
(7) retrospective cohort iOP # 21 mmhg intraoperative MMC intraoperative 5-FU
Abbreviations: IOP, intraocular pressure; TMMC, trabeculectomy augmented with subconjunctival mitomycin C; T5-FU, trabeculectomy augmented with 5-fluorouracil; 
RCT, randomized clinical trial.